T a G Treatment Action Group Inc.

“A draft of form 990 was sent to members of board of directors for review and approval”

“Conflict of interest policy requires board members and key staff to complete an annual disclosure statement. The related individual will be excluded from the discussion and the voting process.”

“Compensation for all employees is reviewed and approved by the executive director. Compensation for the executive director is reviewed and approved by the board of directors.”

“The organization's goverment documents are available upon request. Annual reports are available on the organization's website.”

“Tag works to ensure that all people with hiv receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. Tag catalyzes open collective action by all affected communities, scientists, and policy makers, and global coalitions, to increase the quantity, and improve the quality of research, that can lead to better tb treatment and prevention; precise diagnostics; and preventive vaccines.”

“Tb/hiv project: tuberculosis (tb) kills roughly 1.3 million people each year. Despite being curable, it is the leading cause of death for hiv-positive people globally. Hiv significantly increases the risk for developing tb disease. People at risk for both diseases require tb and hiv services that work together. Tag's tb/hiv project strengthens community-driven advocacy for better tb/hiv research, high-quality programs, and tb/hiv policies worldwide. The project educates, mobilizes, and empowers hiv communities to increase community understanding of tb/hiv coinfection and to take action to reduce tb/hiv coinfection. The project works with researchers, community advocates, policy makers, and global coalitions, to increase the quantity, and improve the quality of research, that can lead to better tb treatment and prevention; precise diagnostics; and preventive vaccines.”

“Hiv project: each day, nearly 4,000 people worldwide die of hiv disease. This immense public health failure can be attributed to a dense web of medical, political, and economic problems. The vast majority of the world's 35 million hiv-positive people live in poor countries where many obstacles prevent the widespread distribution of hiv medications. But even the most effective existing medications have major shortcomings, and hiv-positive people everywhere need better treatment strategies and, ultimately, a cure-one that is scalable, affordable, and can be used worldwide to end the epidemic, along with a safe and effective hiv vaccine. Tag's hiv project reviews the state of research on anti-hiv treatment, development, dissemination, and postmarketing surveillance. The hiv project advocates for accelerated access to treatments; innovation in the development of treatments that are active against drug-resistant hiv; and development of hiv treatments that are easier to take, less toxic, or represent a major therapeutic breakthrough, such as a new drug class. The project advocates for better postmarketing research on approved antiretroviral drugs to improve standards of care; works on domestic and international treatment guidelines; and educates and mobilizes policy makers, researchers, and the hiv community on hiv treatment research. Tag's hiv project works with community members, scientists, and policy makers to enhance public understanding of the science of hiv infection, address gaps in hiv research, critique research efforts, and foster cross-disciplinary collaborations with the aim of accelerating research on hiv pathogenesis and the development of effective immune-based therapies and preventive technologies, with a particular focus on research advocacy around a cure for hiv/aids. The hiv project tracks and analyzes resources devoted to hiv prevention and combined prevention technologies. The project advocates for local, state, and national agencies and aids service organizations to have increased awareness of current prevention tools in order to stop transmission of hiv and thus end the epidemic. In 2014, project members worked on governor cuomo's task force to end aids in new york state by 2020. This effort is part of a broader project by community activists, policy makers, advocates, and researchers to end the epidemic by stemming new infections and ensuring that hiv-positive people receive care, are retained in active care, and remain virally suppressed. Finally, tag's hiv project is developing a cohort of case studies on best practices in community mobilization and how they affect the treatment and care of both people with hiv and those who are hiv-negative. Finally, the hiv project works with global and domestic partners for universal access to high-quality hiv prevention, treatment, and care programs.”

“Hepatitis c virus project: hepatitis c-related liver disease is a leading cause of death among hiv-positive people in the united states and europe. Globally, 5 million hiv-positive people are coinfected with the hepatitis c virus (hcv), while over 175 million have hcv alone. Hiv worsens hcv disease progression and outcomes. Tag's hepatitis/hiv project reviews the state of research on hcv monoinfection and coinfection. It advocates for better and safer treatments, more advanced clinical trial designs, and access to curative treatment for all affected communities. It continually monitors standards of care for people with hcv monoinfection and coinfection. The project works in collaboration with the hcv and hiv communities, scientists, government, and drug companies to provide lifesaving information and safer, more tolerable, and curative hepatitis treatments universally available. In 2012, the project expanded its scope to take on the challenge of accelerating international access to cutting-edge treatment for hcv. With the advent of new short-course all-oral cures for hcv, the project has been collaborating with partners globally to hasten universal, affordable access to these curative medications. In 2014, the project was instrumental in building a global coalition of activists in low- and middle-income countries who are advocating for access to these cures and for care for all people with hcv.”

“The process has not changed since the prior year.”